<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128945</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002796-18</org_study_id>
    <secondary_id>13-090</secondary_id>
    <nct_id>NCT02128945</nct_id>
  </id_info>
  <brief_title>Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies</brief_title>
  <acronym>FLUDATEP</acronym>
  <official_title>Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of positron emission tomography with lymphoproliferative diseases today&#xD;
      provides diagnostic and therapeutic information of major importance , especially in terms of&#xD;
      speed and quality of response to treatment. The radiopharmaceutical used in clinical practice&#xD;
      for this exam is fluorodeoxyglucose 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose&#xD;
      ([18F]-FDG) . However , the uptake of this tracer is not elective in lymphoid tissues , with&#xD;
      a lack of specificity. In addition , the avidity of this tracer is unequal according to the&#xD;
      histological subtype (lack of sensitivity).&#xD;
&#xD;
      To try to improve the results of this clinical exploration of lymphoid malignancies, the&#xD;
      investigators developed a new radiopharmaceutical ( [18F] - fludarabine ). The idea of&#xD;
      transforming the fludarabine radiopharmaceutical is based on the existence of a fluorine atom&#xD;
      in the molecule and the pharmacokinetic characteristics of this drug. The [18F]-Fludarabine&#xD;
      is a new radiopharmaceutical reproducing the same dosage formulation of fludarabine , a drug&#xD;
      used for the treatment of certain types of lymphoproliferative diseases, especially those&#xD;
      where the tumor cells have a low proliferation kinetics . This drug is used in therapy in&#xD;
      particular pharmacokinetic effect for a high affinity for the lymphoid tissue . Preclinical&#xD;
      results on normal and lymphoma xenograft -bearing mice showed a specificity restricted to&#xD;
      lymphoid tissue fixation with [18F]-Fludarabine compared with [18F]-FDG .&#xD;
&#xD;
      Based on these encouraging results , the investigators propose in this work to explore the&#xD;
      Dosimetry and Biodistribution of [18F] - Fludarabine in human lymphoproliferative diseases :&#xD;
      1)A first group of patients with non-Hodgkin's large cell lymphomas in which it already has a&#xD;
      wealth of experience in exploration [18F]-FDG, and 2) a second group of patients with chronic&#xD;
      lymphocytic leukemia, where the results of the exploration [18F]-FDG are considered&#xD;
      disappointing and did not, for this reason, experienced clinical development.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized measure of [18F]-Fludarabine uptake in tumor tissue.</measure>
    <time_frame>Day 0 ([18F]-Fludarabine PET-CT day)</time_frame>
    <description>Measure of the Standard Uptake Value (SUV) for each lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body</measure>
    <time_frame>Day 0 ([18F]-Fludarabine PET-CT day)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Distribution and temporal activity curve of [18F]-Fludarabine obtained for each organ and collection of possible adverse events.</measure>
    <time_frame>Participants will be followed for a maximum of 9 days after [18F]-Fludarabine PET-CT.</time_frame>
    <description>Collection of every adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients</condition>
  <arm_group>
    <arm_group_label>FLUDATEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F] - Fludarabine PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[18F] - Fludarabine PET/CT</intervention_name>
    <description>[18F] - Fludarabine PET/CT before treatment</description>
    <arm_group_label>FLUDATEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult over 18&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Untreated stage B or C chronic lymphocytic leukemia&#xD;
&#xD;
          -  Untreated diffuse large B-cell lymphoma&#xD;
&#xD;
          -  Eligible for PET-CT&#xD;
&#xD;
          -  The subject must be covered by a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Patients concurrently included in an investigational trial&#xD;
&#xD;
          -  Weight over 120 kg&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  active infectious disease&#xD;
&#xD;
          -  immune hemolytic anemia&#xD;
&#xD;
          -  patients with creatinine clearance &lt; 30 ml/mn&#xD;
&#xD;
          -  corticosteroid therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain P CHANTEPIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>Chronic lymphocytic Leukemia (CLL)</keyword>
  <keyword>Diffuse Large B Cells Lymphoma (DLBCL)</keyword>
  <keyword>Fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

